Orphazyme's creditors left without real options

The creditors of embattled biotech firm Orphazyme find themselves between a rock and hard place: There’ll be no money left if they reject a proposed restructuring plan, but if they do that, there will be no company to save.
Photo: Nikolaj Skydsgaard/Reuters/Ritzau Scanpix
Photo: Nikolaj Skydsgaard/Reuters/Ritzau Scanpix
by CHRISTIAN BUNDGAARD, translated by daniel pedersen

Uncertainty continues to surround Orphazyme’s future, even after the proposal of a restructuring plan by the Danish biotech company’s leadership and the restructuring administrator, Gorrissen Federspiel’s John Sommer Schmidt.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading